Modality
ADC
MOA
FGFRi
Target
IL-17A
Pathway
Sphingolipid
MDSWMTTR Amyloidosis
Development Pipeline
Preclinical
Nov 2025
→ Dec 2028
PreclinicalCurrent
NCT06785427
394 pts·WM
2025-11→2028-12·Not yet recruiting
394 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-12-192.7y awayInterim· WM
Trial Timeline
2026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
Preclinical
Not yet…
Catalysts
Interim
2028-12-19 · 2.7y away
WM
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06785427 | Preclinical | WM | Not yet recr... | 394 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 | |
| Rimainavolisib | Illumina | Phase 2 | PD-1 | |
| Elrainavolisib | Roivant Sciences | Preclinical | Nectin-4 | |
| RVM-7089 | Revolution Medicines | Phase 3 | IL-17A | |
| Adagrarapivir | Ideaya Bio | Phase 1/2 | IL-17A |